Ken Griffin Blueprint Medicines Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $235,479 - $337,400	2,800 Added 3.29%	87,900 $8.13 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $1.47 Million - $1.87 Million	17,200 Added 25.33%	85,100 $9.17 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $212,193 - $289,391	2,900 Added 4.46%	67,900 $6.44 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $571,480 - $1.21 Million	13,000 Added 25.0%	65,000 $6 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $483,070 - $679,800	10,300 Added 24.7%	52,000 $2.61 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $573,920 - $902,632	13,600 Added 48.4%	41,700 $2.64 Million
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $561,956 - $740,000	-14,800 Reduced 34.5%	28,100 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $780,140 - $1.26 Million	19,000 Added 79.5%	42,900 $1.88 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $499,300 - $777,000	-10,000 Reduced 29.5%	23,900 $1.58 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.